Unusual global outbreak of monkeypox: what should we do?

Abstract

Recently, monkeypox has become a global concern amid the ongoing COVID-19 pandemic. Monkeypox is an acute rash zoonosis caused by the monkeypox virus, which was previously concentrated in Africa. The re-emergence of this pathogen seems unusual on account of outbreaks in multiple nonendemic countries and the incline to spread from person to person. We need to revisit this virus to prevent the epidemic from getting worse. In this review, we comprehensively summarize studies on monkeypox, including its epidemiology, biological characteristics, pathogenesis, and clinical characteristics, as well as therapeutics and vaccines, highlighting its unusual outbreak attributed to the transformation of transmission. We also analyze the present situation and put forward countermeasures from both clinical and scientific research to address it.

Keywords

monkeypox / poxviruses / vaccine / infectious diseases

References

[1] CDC. 2022 Monkeypox Outbreak Global Map. 2022. Available at the US CDC website (accessed July 8, 2022)

[2] Frey SE, Belshe RB. Poxvirus zoonoses—putting pocks into context. N Engl J Med 2004; 350( 4): 324– 327

[3] Henderson DA. The looming threat of bioterrorism. Science 1999; 283( 5406): 1279– 1282

[4] Weiss MM, Weiss PD, Mathisen G, Guze P. Rethinking smallpox. Clin Infect Dis 2004; 39( 11): 1668– 1673

[5] Bozzette SA, Boer R, Bhatnagar V, Brower JL, Keeler EB, Morton SC, Stoto MA. A model for a smallpox-vaccination policy. N Engl J Med 2003; 348( 5): 416– 425

[6] World Health Assembly. Report of the global commission for the certification of smallpox eradication. World Health Organization: Geneva, 1980

[7] Ladnyj ID, Ziegler P, Kima E. A human infection caused by monkeypox virus in Basankusu Territory, Democratic Republic of the Congo. Bull World Health Organ 1972; 46( 5): 593– 597

[8] Fine PE, Jezek Z, Grab B, Dixon H. The transmission potential of monkeypox virus in human populations. Int J Epidemiol 1988; 17( 3): 643– 650

[9] Grant R, Nguyen LL, Breban R. Modelling human-to-human transmission of monkeypox. Bull World Health Organ 2020; 98( 9): 638– 640

[10] Liu Y, Rocklöv J. The effective reproductive number of the Omicron variant of SARS-CoV-2 is several times relative to Delta. J Travel Med 2022; 29( 3): taac037

[11] Magnus P, Andersen EK, Petersen KB, Birch-Andersen A. A pox-like disease in cynomolgus monkeys. Acta Pathol Microbiol Scand 1959; 46( 2): 156– 176

[12] Sklenovská N, Van Ranst M. Emergence of monkeypox as the most important orthopoxvirus infection in humans. Front Public Health 2018; 6 : 241

[13] Reynolds MG, Carroll DS, Karem KL. Factors affecting the likelihood of monkeypox’s emergence and spread in the post-smallpox era. Curr Opin Virol 2012; 2( 3): 335– 343

[14] Schneider KA Eichner M. Does it matter who is spreading monkeypox? Lancet Infect Dis 2022; [Epub ahead of print] doi:10.1016/S1473-3099(22)00431-5

[15] Wenner HA, Macasaet FD, Kamitsuka PS, Kidd P. Monkey pox. I. Clinical, virologic and immunologic studies. Am J Epidemiol 1968; 87( 3): 551– 566

[16] Prier JE, Sauer RM. A pox disease of monkeys. Ann N Y Acad Sci 1960; 85( 3): 951– 959

[17] Nakoune E, Lampaert E, Ndjapou SG, Janssens C, Zuniga I, Van Herp M, Fongbia JP, Koyazegbe TD, Selekon B, Komoyo GF, Garba-Ouangole SM, Manengu C, Manuguerra JC, Kazanji M, Gessain A, Berthet N. A nosocomial outbreak of human monkeypox in the Central African Republic. Open Forum Infect Dis 2017; 4( 4): ofx168

[18] Marennikova SS, Seluhina EM, Mal’ceva NN, Cimiskjan KL, Macevic GR. Isolation and properties of the causal agent of a new variola-like disease (monkeypox) in man. Bull World Health Organ 1972; 46( 5): 599– 611

[19] Sklenovská N, Van Ranst M. Emergence of monkeypox as the most important orthopoxvirus infection in humans. Front Public Health 2018; 6 : 241

[20] Durski KN, McCollum AM, Nakazawa Y, Petersen BW, Reynolds MG, Briand S, Djingarey MH, Olson V, Damon IK, Khalakdina A. Emergence of monkeypox—West and Central Africa, 1970–2017. MMWR Morb Mortal Wkly Rep 2018; 67( 10): 306– 310

[21] Quiner CA, Moses C, Monroe BP, Nakazawa Y, Doty JB, Hughes CM, McCollum AM, Ibata S, Malekani J, Okitolonda E, Carroll DS, Reynolds MG. Presumptive risk factors for monkeypox in rural communities in the Democratic Republic of the Congo. PLoS One 2017; 12( 2): e0168664

[22] Bunge EM, Hoet B, Chen L, Lienert F, Weidenthaler H, Baer LR, Steffen R. The changing epidemiology of human monkeypox—a potential threat? A systematic review. PLoS Negl Trop Dis 2022; 16( 2): e0010141

[23] Adegboye OA, Eugenia Castellanos M, Alele FO, Pak A, Ezechukwu HC, Hou K, Emeto TI. Travel-related monkeypox outbreaks in the era of COVID-19 pandemic: are we prepared? Viruses 2022; 14(6): 1283 doi:10.3390/v14061283

[24] Hughes AL, Irausquin S, Friedman R. The evolutionary biology of poxviruses. Infect Genet Evol 2010; 10( 1): 50– 59

[25] Zheng L, Meng J, Lin M, Lv R, Cheng H, Zou L, Sun J, Li L, Ren R, Wang S. Structure prediction of the entire proteome of monkeypox variants. Acta Materia Medica 2022; 1( 2): 260– 264

[26] Vandenbogaert M, Kwasiborski A, Gonofio E, Descorps-Declère S, Selekon B, Nkili Meyong AA, Ouilibona RS, Gessain A, Manuguerra JC, Caro V, Nakoune E, Berthet N. Nanopore sequencing of a monkeypox virus strain isolated from a pustular lesion in the Central African Republic. Sci Rep 2022; 12( 1): 10768

[27] Shchelkunov SN, Totmenin AV, Safronov PF, Mikheev MV, Gutorov VV, Ryazankina OI, Petrov NA, Babkin IV, Uvarova EA, Sandakhchiev LS, Sisler JR, Esposito JJ, Damon IK, Jahrling PB, Moss B. Analysis of the monkeypox virus genome. Virology 2002; 297( 2): 172– 194

[28] Babkin IV, Babkina IN, Tikunova NV. An update of orthopoxvirus molecular evolution. Viruses 2022; 14( 2): 388

[29] Isidro J Borges V Pinto M Sobral D Santos JD Nunes A Mixão V Ferreira R Santos D Duarte S Vieira L Borrego MJ Núncio S de Carvalho IL Pelerito A Cordeiro R Gomes JP. Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus. Nat Med 2022; [Epub ahead of print] doi:10.1038/s41591-022-01907-y

[30] Parker S, Nuara A, Buller RM, Schultz DA. Human monkeypox: an emerging zoonotic disease. Future Microbiol 2007; 2( 1): 17– 34

[31] Nalca A, Rimoin AW, Bavari S, Whitehouse CA. Reemergence of monkeypox: prevalence, diagnostics, and countermeasures. Clin Infect Dis 2005; 41( 12): 1765– 1771

[32] Rimoin AW, Mulembakani PM, Johnston SC, Lloyd Smith JO, Kisalu NK, Kinkela TL, Blumberg S, Thomassen HA, Pike BL, Fair JN, Wolfe ND, Shongo RL, Graham BS, Formenty P, Okitolonda E, Hensley LE, Meyer H, Wright LL, Muyembe JJ. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci USA 2010; 107( 37): 16262– 16267

[33] Hutson CL, Olson VA, Carroll DS, Abel JA, Hughes CM, Braden ZH, Weiss S, Self J, Osorio JE, Hudson PN, Dillon M, Karem KL, Damon IK, Regnery RL. A prairie dog animal model of systemic orthopoxvirus disease using West African and Congo Basin strains of monkeypox virus. J Gen Virol 2009; 90( 2): 323– 333

[34] Rao AK, Schulte J, Chen TH, Hughes CM, Davidson W, Neff JM, Markarian M, Delea KC, Wada S, Liddell A, Alexander S, Sunshine B, Huang P, Honza HT, Rey A, Monroe B, Doty J, Christensen B, Delaney L, Massey J, Waltenburg M, Schrodt CA, Kuhar D, Satheshkumar PS, Kondas A, Li Y, Wilkins K, Sage KM, Yu Y, Yu P, Feldpausch A, McQuiston J, Damon IK, McCollum AM; July 2021 Monkeypox Response Team. Monkeypox in a traveler returning from Nigeria—Dallas, Texas, July 2021. MMWR Morb Mortal Wkly Rep 2022; 71( 14): 509– 516

[35] Kisalu NK, Mokili JL. Toward understanding the outcomes of monkeypox infection in human pregnancy. J Infect Dis 2017; 216( 7): 795– 797

[36] Silva NIO, de Oliveira JS, Kroon EG, Trindade GS, Drumond BP. Here, there, and everywhere: the wide host range and geographic distribution of zoonotic orthopoxviruses. Viruses 2020; 13( 1): 43

[37] Bonilla-Aldana DK, Rodriguez-Morales AJ. Is monkeypox another reemerging viral zoonosis with many animal hosts yet to be defined? Vet Q 2022; 42(1): 148–150 doi:10.1080/01652176.2022.2088881

[38] Kupferschmidt K. Why monkeypox is mostly hitting men who have sex with men. Science 2022; 376( 6600): 1364– 1365

[39] Heskin J Belfield A Milne C Brown N Walters Y Scott C Bracchi M Moore LS Mughal N Rampling T Winston A Nelson M Duncan S Jones R Price DA Mora-Peris B. Transmission of monkeypox virus through sexual contact — a novel route of infection. J Infect 2022; [Epub ahead of print] doi:10.1016/j.jinf.2022.05.028

[40] Bellinato F Gisondi P Girolomoni G. Monkeypox virus infection: what dermatologist needs to know? J Eur Acad Dermatol Venereol 2022; [Epub ahead of print] doi:10.1111/jdv.18299

[41] Kabuga AI, El Zowalaty ME. A review of the monkeypox virus and a recent outbreak of skin rash disease in Nigeria. J Med Virol 2019; 91( 4): 533– 540

[42] Girometti N Byrne R Bracchi M Heskin J McOwan A Tittle V Gedela K Scott C Patel S Gohil J Nugent D Suchak T Dickinson M Feeney M Mora-Peris B Stegmann K Plaha K Davies G Moore LSP Mughal N Asboe D Boffito M Jones R Whitlock G. Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysis. Lancet Infect Dis 2022; [Epub ahead of print] doi:10.1016/S1473-3099(22)00411-X

[43] Fenner F. The pathogenesis of the acute exanthems; an interpretation based on experimental investigations with mousepox; infectious ectromelia of mice. Lancet 1948; 252( 6537): 915– 920

[44] Shepardson KM, Schwarz B, Larson K, Morton RV, Avera J, McCoy K, Caffrey A, Harmsen A, Douglas T, Rynda-Apple A. Induction of antiviral immune response through recognition of the repeating subunit pattern of viral capsids is Toll-like receptor 2 dependent. MBio 2017; 8( 6): e01356– e01317

[45] Yu H, Bruneau RC, Brennan G, Rothenburg S. Battle royale: innate recognition of poxviruses and viral immune evasion. Biomedicines 2021; 9( 7): 765

[46] Hammarlund E, Dasgupta A, Pinilla C, Norori P, Früh K, Slifka MK. Monkeypox virus evades antiviral CD4⁺ and CD8⁺ T cell responses by suppressing cognate T cell activation. Proc Natl Acad Sci USA 2008; 105( 38): 14567– 14572

[47] Kindrachuk J, Arsenault R, Kusalik A, Kindrachuk KN, Trost B, Napper S, Jahrling PB, Blaney JE. Systems kinomics demonstrates Congo Basin monkeypox virus infection selectively modulates host cell signaling responses as compared to West African monkeypox virus. Mol Cell Proteomics 2012; 11( 6): M111.015701

[48] Estep RD, Messaoudi I, O’Connor MA, Li H, Sprague J, Barron A, Engelmann F, Yen B, Powers MF, Jones JM, Robinson BA, Orzechowska BU, Manoharan M, Legasse A, Planer S, Wilk J, Axthelm MK, Wong SW. Deletion of the monkeypox virus inhibitor of complement enzymes locus impacts the adaptive immune response to monkeypox virus in a nonhuman primate model of infection. J Virol 2011; 85( 18): 9527– 9542

[49] Miura F, van Ewijk CE, Backer JA, Xiridou M, Franz E, Op de Coul E, Brandwagt D, van Cleef B, van Rijckevorsel G, Swaan C, van den Hof S, Wallinga J. Estimated incubation period for monkeypox cases confirmed in the Netherlands, May 2022. Euro Surveill 2022; 27( 24): 2200448

[50] Petersen E, Kantele A, Koopmans M, Asogun D, Yinka-Ogunleye A, Ihekweazu C, Zumla A. Human monkeypox: epidemiologic and clinical characteristics, diagnosis, and prevention. Infect Dis Clin North Am 2019; 33( 4): 1027– 1043

[51] Adler H Gould S Hine P Snell LB Wong W Houlihan CF Osborne JC Rampling T Beadsworth MB Duncan CJ Dunning J Fletcher TE Hunter ER Jacobs M Khoo SH Newsholme W Porter D Porter RJ Ratcliffe L Schmid ML Semple MG Tunbridge AJ Wingfield T Price NM; NHS England High Consequence Infectious Diseases (Airborne) Network. Clinical features and management of human monkeypox: a retrospective observational study in the UK. Lancet Infect Dis 2022; [Epub ahead of print] doi:10.1016/S1473-3099(22)00228-6

[52] McCollum AM, Damon IK. Human monkeypox. Clin Infect Dis 2014; 58( 2): 260– 267

[53] Erez N, Achdout H, Milrot E, Schwartz Y, Wiener-Well Y, Paran N, Politi B, Tamir H, Israely T, Weiss S, Beth-Din A, Shifman O, Israeli O, Yitzhaki S, Shapira SC, Melamed S, Schwartz E. Diagnosis of imported monkeypox, Israel, 2018. Emerg Infect Dis 2019; 25( 5): 980– 983

[54] Yinka-Ogunleye A, Aruna O, Dalhat M, Ogoina D, McCollum A, Disu Y, Mamadu I, Akinpelu A, Ahmad A, Burga J, Ndoreraho A, Nkunzimana E, Manneh L, Mohammed A, Adeoye O, Tom-Aba D, Silenou B, Ipadeola O, Saleh M, Adeyemo A, Nwadiutor I, Aworabhi N, Uke P, John D, Wakama P, Reynolds M, Mauldin MR, Doty J, Wilkins K, Musa J, Khalakdina A, Adedeji A, Mba N, Ojo O, Krause G, Ihekweazu C; CDC Monkeypox Outbreak Team. Outbreak of human monkeypox in Nigeria in 2017–18: a clinical and epidemiological report. Lancet Infect Dis 2019; 19( 8): 872– 879

[55] Macneil A, Reynolds MG, Braden Z, Carroll DS, Bostik V, Karem K, Smith SK, Davidson W, Li Y, Moundeli A, Mombouli JV, Jumaan AO, Schmid DS, Regnery RL, Damon IK. Transmission of atypical varicella-zoster virus infections involving palm and sole manifestations in an area with monkeypox endemicity. Clin Infect Dis 2009; 48( 1): e6– e8

[56] Patrocinio-Jesus R, Peruzzu F. Monkeypox genital lesions. N Engl J Med 2022; 387( 1): 66

[57] Walter K Malani PN. What is monkeypox? JAMA 2022; [Epub ahead of print] doi:10.1001/jama.2022.10259

[58] Hughes CM, Liu L, Davidson WB, Radford KW, Wilkins K, Monroe B, Metcalfe MG, Likafi T, Lushima RS, Kabamba J, Nguete B, Malekani J, Pukuta E, Karhemere S, Muyembe Tamfum JJ, Okitolonda Wemakoy E, Reynolds MG, Schmid DS, McCollum AM. A tale of two viruses: coinfections of monkeypox and varicella zoster virus in the Democratic Republic of Congo. Am J Trop Med Hyg 2021; 104( 2): 604– 611

[59] Di Giulio DB, Eckburg PB. Human monkeypox: an emerging zoonosis. Lancet Infect Dis 2004; 4( 1): 15– 25

[60] Rizk JG Lippi G Henry BM Forthal DN Rizk Y. Prevention and treatment of monkeypox. Drugs 2022; [Epub ahead of print] doi:10.1007/s40265-022-01742-y

[61] Hoy SM. Tecovirimat: first global approval. Drugs 2018; 78( 13): 1377– 1382

[62] Grosenbach DW, Honeychurch K, Rose EA, Chinsangaram J, Frimm A, Maiti B, Lovejoy C, Meara I, Long P, Hruby DE. Oral Tecovirimat for the treatment of smallpox. N Engl J Med 2018; 379( 1): 44– 53

[63] Alvarez-Cardona JJ, Whited LK, Chemaly RF. Brincidofovir: understanding its unique profile and potential role against adenovirus and other viral infections. Future Microbiol 2020; 15( 6): 389– 400

[64] Chittick G, Morrison M, Brundage T, Nichols WG. Short-term clinical safety profile of brincidofovir: a favorable benefit-risk proposition in the treatment of smallpox. Antiviral Res 2017; 143 : 269– 277

[65] De Clercq E. Cidofovir in the therapy and short-term prophylaxis of poxvirus infections. Trends Pharmacol Sci 2002; 23( 10): 456– 458

[66] Kravcik S. Cidofovir for cytomegalovirus retinitis. Ann Intern Med 1997; 127( 6): 490– 491

[67] Holland GN, Van Natta ML, Goldenberg DT, Ritts R Jr, Danis RP, Jabs DA; Studies of Ocular Complications of AIDS Research Group. Relationship between opacity of cytomegalovirus retinitis lesion borders and severity of immunodeficiency among people with AIDS. Invest Ophthalmol Vis Sci 2019; 60( 6): 1853– 1862

[68] Wittek R. Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy. Int J Infect Dis 2006; 10( 3): 193– 201

[69] Hopkins RJ, Kramer WG, Blackwelder WC, Ashtekar M, Hague L, Winker-La Roche SD, Berezuk G, Smith D, Leese PT. Safety and pharmacokinetic evaluation of intravenous vaccinia immune globulin in healthy volunteers. Clin Infect Dis 2004; 39( 6): 759– 766

[70] Petersen BW, Damon IK, Pertowski CA, Meaney-Delman D, Guarnizo JT, Beigi RH, Edwards KM, Fisher MC, Frey SE, Lynfield R, Willoughby RE. Clinical guidance for smallpox vaccine use in a postevent vaccination program. MMWR Recomm Rep 2015; 64( RR–02): 1– 26

[71] Gilbert SC. Clinical development of Modified Vaccinia virus Ankara vaccines. Vaccine 2013; 31( 39): 4241– 4246

[72] Overton ET, Lawrence SJ, Stapleton JT, Weidenthaler H, Schmidt D, Koenen B, Silbernagl G, Nopora K, Chaplin P. A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDS. Vaccine 2020; 38( 11): 2600– 2607

[73] Volz A, Sutter G. Modified Vaccinia virus Ankara: history, value in basic research, and current perspectives for vaccine development. Adv Virus Res 2017; 97 : 187– 243

[74] Greenberg RN, Kennedy JS. ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine. Expert Opin Investig Drugs 2008; 17( 4): 555– 564

[75] Russell PK. Vaccines in civilian defense against bioterrorism. Emerg Infect Dis 1999; 5( 4): 531– 533

[76] Talbot TR, Stapleton JT, Brady RC, Winokur PL, Bernstein DI, Germanson T, Yoder SM, Rock MT, Crowe JE Jr, Edwards KM. Vaccination success rate and reaction profile with diluted and undiluted smallpox vaccine: a randomized controlled trial. JAMA 2004; 292( 10): 1205– 1212

[77] Hou J, Wang S, Li D, Carpp LN, Zhang T, Liu Y, Jia M, Peng H, Liu C, Wu H, Huang Y, Shao Y. Early pro-inflammatory signal and T-cell activation associate with vaccine-induced anti-vaccinia protective neutralizing antibodies. Front Immunol 2021; 12 : 737487

[78] Wen B, Deng Y, Chen H, Guan J, Chuai X, Ruan L, Kong W, Tan W. The novel replication-defective vaccinia virus (Tiantan strain)-based hepatitis C virus vaccine induces robust immunity in macaques. Mol Ther 2013; 21( 9): 1787– 1795

[79] Deng Y, Chuai X, Chen P, Chen H, Wang W, Ruan L, Li W, Tan W. Recombinant vaccinia vector-based vaccine (Tiantan) boosting a novel HBV subunit vaccine induced more robust and lasting immunity in rhesus macaques. Vaccine 2017; 35( 25): 3347– 3353

[80] Liu Q, Li Y, Luo Z, Yang G, Liu Y, Liu Y, Sun M, Dai J, Li Q, Qin C, Shao Y. HIV-1 vaccines based on replication-competent Tiantan vaccinia protected Chinese rhesus macaques from simian HIV infection. AIDS 2015; 29( 6): 649– 658

[81] Merchlinsky M, Albright A, Olson V, Schiltz H, Merkeley T, Hughes C, Petersen B, Challberg M. The development and approval of tecoviromat (TPOXX^®), the first antiviral against smallpox. Antiviral Res 2019; 168 : 168– 174

[82] Russo AT, Berhanu A, Bigger CB, Prigge J, Silvera PM, Grosenbach DW, Hruby D. Co-administration of tecovirimat and ACAM2000™ in non-human primates: effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge. Vaccine 2020; 38( 3): 644– 654

[83] Russo AT, Grosenbach DW, Brasel TL, Baker RO, Cawthon AG, Reynolds E, Bailey T, Kuehl PJ, Sugita V, Agans K, Hruby DE. Effects of treatment delay on efficacy of Tecovirimat following lethal aerosol monkeypox virus challenge in cynomolgus macaques. J Infect Dis 2018; 218( 9): 1490– 1499

[84] Berhanu A, Prigge JT, Silvera PM, Honeychurch KM, Hruby DE, Grosenbach DW. Treatment with the smallpox antiviral tecovirimat (ST-246) alone or in combination with ACAM2000 vaccination is effective as a postsymptomatic therapy for monkeypox virus infection. Antimicrob Agents Chemother 2015; 59( 7): 4296– 4300

[85] Whitehouse ER, Rao AK, Yu YC, Yu PA, Griffin M, Gorman S, Angel KA, McDonald EC, Manlutac AL, de Perio MA, McCollum AM, Davidson W, Wilkins K, Ortega E, Satheshkumar PS, Townsend MB, Isakari M, Petersen BW. Novel treatment of a vaccinia virus infection from an occupational needlestick—San Diego, California, 2019. MMWR Morb Mortal Wkly Rep 2019; 68( 42): 943– 946

[86] Grosenbach DW, Honeychurch K, Rose EA, Chinsangaram J, Frimm A, Maiti B, Lovejoy C, Meara I, Long P, Hruby DE. Oral Tecovirimat for the treatment of smallpox. N Engl J Med 2018; 379( 1): 44– 53

[87] Earl PL, Americo JL, Wyatt LS, Eller LA, Whitbeck JC, Cohen GH, Eisenberg RJ, Hartmann CJ, Jackson DL, Kulesh DA, Martinez MJ, Miller DM, Mucker EM, Shamblin JD, Zwiers SH, Huggins JW, Jahrling PB, Moss B. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 2004; 428( 6979): 182– 185

[88] Earl PL, Americo JL, Wyatt LS, Espenshade O, Bassler J, Gong K, Lin S, Peters E, Rhodes L Jr, Spano YE, Silvera PM, Moss B. Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. Proc Natl Acad Sci USA 2008; 105( 31): 10889– 10894

[89] Stittelaar KJ, van Amerongen G, Kondova I, Kuiken T, van Lavieren RF, Pistoor FHM, Niesters HGM, van Doornum G, van der Zeijst BAM, Mateo L, Chaplin PJ, Osterhaus ADME. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J Virol 2005; 79( 12): 7845– 7851

[90] McCurdy LH, Larkin BD, Martin JE, Graham BS. Modified vaccinia Ankara: potential as an alternative smallpox vaccine. Clin Infect Dis 2004; 38( 12): 1749– 1753

[91] Phelps AL, Gates AJ, Hillier M, Eastaugh L, Ulaeto DO. Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine. Vaccine 2007; 25( 1): 34– 42

[92] Overton ET, Lawrence SJ, Wagner E, Nopora K, Rösch S, Young P, Schmidt D, Kreusel C, De Carli S, Meyer TP, Weidenthaler H, Samy N, Chaplin P. Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: a randomised, double blind, placebo controlled phase III trial. PLoS One 2018; 13( 4): e0195897

[93] Greenberg RN, Hay CM, Stapleton JT, Marbury TC, Wagner E, Kreitmeir E, Röesch S, von Krempelhuber A, Young P, Nichols R, Meyer TP, Schmidt D, Weigl J, Virgin G, Arndtz-Wiedemann N, Chaplin P. A randomized, double-blind, placebo-controlled phase II trial investigating the safety and immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-year-old subjects. PLoS One 2016; 11( 6): e0157335

[94] Brown K, Leggat PA. Human monkeypox: current state of knowledge and implications for the future. Trop Med Infect Dis 2016; 1( 1): 8

Rights & permissions

Higher Education Press